Immatics Current Liabilities Trend from 2010 to 2022

IMTX
 Stock
  

USD 8.91  0.20  2.30%   

Immatics Current Liabilities yearly trend continues to be fairly stable with very little volatility. Current Liabilities will likely drop to about 89 M in 2022. During the period from 2010 to 2022, Immatics Current Liabilities regression line of anual values had slope of 5,738,023 and arithmetic mean of  44,033,951. Immatics Interest Expense is fairly stable at the moment as compared to the past year. Immatics reported Interest Expense of 1.73 Million in 2021. Net Income to Non Controlling Interests is likely to rise to about 598.4 K in 2022, whereas Consolidated Income is likely to drop (100.7 M) in 2022.
  
Refresh
Check Immatics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics main balance sheet or income statement drivers, such as Gross Profit of 31.1 M, Interest Expense of 2.7 M or Net Income to Non Controlling Interests of 598.4 K, as well as many exotic indicators such as Asset Turnover of 0.18, Book Value per Share of 0.41 or Current Ratio of 1.74. Immatics financial statements analysis is a perfect complement when working with Immatics Valuation or Volatility modules. It can also supplement various Immatics Technical models. Please see the analysis of Immatics Correlation against competitors.

Immatics Quarterly Current Liabilities

91.85 Million

Share

Immatics Current Liabilities Breakdown

Showing smoothed Current Liabilities of Immatics NV with missing and latest data points interpolated. The current portion of Total Liabilities; reported if the company operates a classified balance sheet that segments current and non-current liabilities.Immatics' Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics' overall financial position and show how it may be relating to other accounts over time.
Current Liabilities10 Years Trend
Increasing
Slightly volatile
 Current Liabilities 
Share
      Timeline 

Immatics Current Liabilities Regression Statistics

Arithmetic Mean 44,033,951
Geometric Mean 37,859,793
Coefficient Of Variation 62.37
Mean Deviation 23,809,779
Median 26,838,000
Standard Deviation 27,462,913
Range 68,310,000
R-Value 0.81
R-Squared 0.66
Significance 0.00071362
Slope 5,738,023

Immatics Current Liabilities History

201969.3 M
202077.5 M
202195.1 M
202289 M

About Immatics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immatics income statement, its balance sheet, and the statement of cash flows. Immatics investors use historical funamental indicators, such as Immatics's Current Liabilities, to determine how well the company is positioned to perform in the future. Although Immatics investors may use each financial statement separately, they are all related. The changes in Immatics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immatics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immatics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immatics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Current Liabilities95.1 M89 M
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 373 people.

Immatics Investors Sentiment

The influence of Immatics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immatics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Immatics Implied Volatility

    
  114.66  
Immatics' implied volatility exposes the market's sentiment of Immatics NV stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immatics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immatics stock will not fluctuate a lot when Immatics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immatics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immatics' short interest history, or implied volatility extrapolated from Immatics options trading.

Current Sentiment - IMTX

Immatics NV Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immatics NV. What is your judgment towards investing in Immatics NV? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immatics Correlation against competitors. Note that the Immatics NV information on this page should be used as a complementary analysis to other Immatics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Immatics Stock analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
560.7 M
Quarterly Revenue Growth YOY
12.9
Return On Assets
0.0145
Return On Equity
0.16
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.